论文部分内容阅读
核心蛋白聚糖(DCN)属富含亮氨酸小分子蛋白多糖家族成员之一。转化生长因子β(TGF-β)与其受体结合后导致细胞外基质过度沉积,DCN通过与TGF-β结合并将其中和以产生抗纤维化和抑制瘢痕形成的作用。同时DCN亦通过激活表皮生长因子受体(EGFR)/促分裂原活化蛋白激酶/p21信号通路和抑制EGF-EGFR介导的促细胞增殖信号通路等机制来抑制肿瘤细胞增殖与转移。基于DCN以上两方面的生物活性,加之源于人体自身产生,所以重组产品免疫原性较低,提示DCN对于慢性纤维化和肿瘤等疾病的防治具有潜在的药用开发价值。
Dendritin (DCN) is a member of the leucine-rich small molecule proteoglycan family. Transforming growth factor beta (TGF-beta) binds to its receptor resulting in excessive deposition of the extracellular matrix, which acts by binding to TGF-beta and neutralizing it to produce antifibrosis and inhibit scarring. Meanwhile, DCN also inhibits tumor cell proliferation and metastasis by activating the EGFR / mitogen-activated protein kinase / p21 signaling pathway and inhibiting the EGF-EGFR-mediated cell proliferation signaling pathway. Based on the above two aspects of biological activity of DCN, combined with its own production from the human body, so the low immunogenicity of recombinant products, suggesting that DCN for the prevention and treatment of chronic fibrosis and oncology and other potential pharmaceutical development value.